Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. [electronic resource]
Producer: 20160609Description: 443-51 p. digitalISSN:- 1527-7755
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- genetics
- Capecitabine -- administration & dosage
- Double-Blind Method
- Esophageal Neoplasms -- drug therapy
- Esophagogastric Junction -- drug effects
- Female
- Follow-Up Studies
- Gene Amplification
- Humans
- Lapatinib
- Lymphatic Metastasis
- Male
- Middle Aged
- Neoplasm Staging
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Polymerase Chain Reaction
- Prognosis
- Quinazolines -- administration & dosage
- Receptor, ErbB-2 -- genetics
- Stomach Neoplasms -- drug therapy
- Survival Rate
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.